Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kristel Polder

Dermatology Dallas, TX Medical Doctor

NPI 1629234364 CMS profile 346508

8201 Preston Rd., Ste 350, Dallas, TX 75225

Open in the dashboard

General payments

$79,845

382 records reported · program years 2019–2025

Research payments

$208

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$680,670 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kristel Polder of Dallas, TX is reported in the CMS Open Payments database as having received $79,845 across 382 general payments and $208 in research payments paid to them. Separately, studies naming them as principal investigator received $680,670 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,141 50
2025 Research $208 6
2024 General $18,058 65
2023 General $26,660 63
2022 General $6,317 45
2021 General $19,243 69
2020 General $5,190 43
2019 General $3,237 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristel Polder
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kristel Polder were reported at $1,141. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kristel Polder Dermatology median Middle half National median
2019 $3,237 $454 $129–$1,240 $163
2020 $5,190 $235 $81–$756 $114
2021 $19,243 $377 $108–$1,108 $132
2022 $6,317 $514 $143–$1,391 $149
2023 $26,660 $607 $159–$1,674 $160
2024 $18,058 $751 $204–$1,903 $164
2025 $1,141 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $35,114 129 payments
  2. Allergan Inc. $31,288 95 payments
  3. Solta Medical, a division of Bausch Health US, LLC $9,962 14 payments
  4. Aclaris Therapeutics, Inc. $564 7 payments
  5. Galderma Laboratories, L.P. $483 31 payments
  6. Sun Pharmaceutical Industries Inc. $388 17 payments
  7. Lilly USA, LLC $253 7 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $205 11 payments
  9. Pfizer Inc. $173 11 payments
  10. Mayne Pharma Inc. $171 7 payments
  11. Other $1,244 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,618 17 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,300 4 payments
  3. Food and Beverage $8,718 345 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $6,000 2 payments
  5. Travel and Lodging $4,209 14 payments
Products named General payments · program years 2019–2025
  1. BOTOX $29,155 120 payments
  2. BOTOX COSMETIC $6,501 14 payments
  3. CLEAR+BRILLIANT $3,135 3 payments
  4. ESKATA $512 2 payments
  5. SKYRIZI $409 18 payments
  6. Clear & Brilliant $363 2 payments
  7. Winlevi $238 10 payments
  8. RINVOQ $224 4 payments
  9. Absorica LD $220 10 payments
  10. EUCRISA $173 11 payments
  11. Other $3,200 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $208 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

167

Median for Dermatology: 534

Drug cost

$2,025

Median for Dermatology: $67,151

Branded share of claims

21%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Triamcinolone Acetonide Generic 47 $528
Ketoconazole Generic 17 $387
Clindamycin-Benzoyl Peroxide Clindamycin Phos/Benzoyl Perox Brand 13 $339
Doxycycline Hyclate Generic 14 $308
Valacyclovir Valacyclovir Hcl Brand 22 $159
Mupirocin Generic 26 $135
Fluconazole Generic 13 $85
Hydrocortisone Generic 15 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$43,821

Medicare's payments for the services billed

Medicare patients

228

Average age 74

Services billed

1,155

155 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 51%
Arthritis 42%
Osteoporosis 20%
Ischemic heart disease 18%
Cancer 17%
Atrial fibrillation 11%
Depression 11%
Diabetes 8%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $10,984
$10,984 — —
SKYRIZI
  • AbbVie, Inc. $213
$213 — —
VTAMA
  • Dermavant Sciences, Inc. $55
$55 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $42
$42 — —
Winlevi
  • Sun Pharmaceutical Industries Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record